Enliven Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
Enliven Therapeutics, Inc. (ELVN) filed a Current Report on Form 8-K on June 11, 2026. The filing reports the entry into a material definitive agreement for a public offering of common stock and pre-funded warrants. The company is incorporated in Delaware and its principal executive offices are located in Burlingame, California.
Key Financial Metrics and Offering Details
This filing details a capital raise rather than operational financial results. Key metrics regarding the offering include:
- Offering Price: $37.50 per share for common stock; $37.499 per pre-funded warrant.
- Shares Issued: 8,933,334 shares of common stock (Firm Shares).
- Pre-Funded Warrants: 1,733,333 warrants issued in lieu of shares to certain investors, exercisable at $0.001 per share.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 1,600,000 additional shares.
- Expected Net Proceeds: Approximately $376.0 million (base case) or $432.4 million (if over-allotment is fully exercised), after deducting underwriting discounts and estimated offering expenses.
- Expected Closing Date: June 15, 2026.
The filing does not provide current revenue, profit, cash flow, or debt metrics for the company's operations.
Material Changes
The primary material change is the execution of an underwriting agreement with Jefferies LLC, Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, and Barclays Capital Inc. This transaction represents a significant increase in the company's equity capital and outstanding share count upon closing.
Guidance, Outlook, and Risks
Management Commentary: The company issued a press release on June 11, 2026, announcing the pricing of the offering. The proceeds are intended to fund the company's operations, though specific allocation details are not provided in this text.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Risks include uncertainties related to market conditions and the satisfaction of customary closing conditions. The actual closing date and net proceeds may differ from expectations. The pre-funded warrants contain limitations on exercise to prevent beneficial ownership exceeding 4.99% (or up to 9.99% or 19.99% with notice) of the total outstanding shares.
Investor Verification Checklist
- Verify the final closing date of the offering (expected June 15, 2026) and whether the over-allotment option was exercised.
- Confirm the final net proceeds received by the company after all expenses.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific indemnification obligations and termination provisions.
- Check subsequent filings for the updated number of shares outstanding and the impact on per-share metrics.
- Review the company's most recent 10-K or 10-Q for current liquidity, cash burn rate, and operational progress, as this 8-K does not contain operational financial data.